Nina Mojas

President, Global Product Strategy and member of the Executive Committee @ GSK

Country

Switzerland

City

Zug

Industry

Pharmaceuticals

Skill

Pharmaceutical Industry, Biotechnology, Molecular Biology, Cell Biology, Biochemistry, Cancer, Oncology, Cell Culture, Clinical Development, Financial Analysis, Strategic Thinking, Corporate Communications, Investment Strategies, Investor Relations, Clinical Trials, Lifesciences, Strategy, Drug Development, Cancer Research, Drug Discovery

Experience

President, Global Product Strategy and member of the Executive Committee

GSK

2026-1 - Present · 9 mos

Zug, Zug, Switzerland

Senior Vice President, Oncology Global Product Strategy

GSK

2022-2 - 2026-1 · 4 yrs

Zug, Switzerland

Vice President Oncology

GSK

2020-5 - 2022-2 · 1 yr 10 mos

Zug, Switzerland

Immuno-Oncology

Oncology Business Unit Director

AstraZeneca

2018-7 - 2020-4 · 1 yr 10 mos

Baar, Canton of Zug, Switzerland

VP, Lynparza Global Medicines Leader (GML)

AstraZeneca

2016-2 - 2018-6 · 2 yrs 5 mos

Cambridge, United Kingdom

• “CEO of an asset”, leading a cross functional team accountable for all aspects of clinical development, biomarker selection, regulatory strategies and commercialisation • Managing first-in-class PARP inhibitor program, with extensive development in six tumour types and a complex, pioneering biomarker program

VP Oncology Evaluation and Early Portfolio

AstraZeneca

2014-5 - 2016-1 · 1 yr 9 mos

Cambridge, United Kingdom

• Member of Oncology Leadership Team, accountable for business development strategy and leading a team responsible for partnering and acquisitions of external assets • Led acquisition of Acerta, the US haematology company with best-in-class BTK inhibitor, subsequently approved by the FDA. It was AZ’s largest acquisition since MedImmune in 2007 • Led the in-licencing of monalizumab (anti-NKG2A) from Innate Pharma • Instrumental in establishing multiple collaborations between AZ Oncology portfolio and complementary external assets • In addition to leading Oncology Business Development, tasked to build a team of Early Portfolio Directors, responsible for strategic guidance of assets in early clinical development (Ph1 and 2) and their transition into Late Stage Development

Investor Relations Officer

Roche

2009-12 - 2014-5 · 4 yrs 6 mos

•Communication to financial analysts and investors •Responsible for preparation of Roche external presentation with financial results, business drivers and pipeline developments •Senior management support ahead of results announcements (information gathering, selection and presentation, critical issues handling...) •Presentation of IR strategy and goals to the senior management •Responsible for collection and analysis of Roche consensus expectations, comparing to internal business plans, guiding the analysts' expectations •Organization of analyst meetings at scientific conferences (ASCO) •Organization of pipeline events and R&D investor meetings

Healthcare Specialist

Kepler Cheuvreux

2007 - 2009-12 · 3 yrs

•Advising on investments in healthcare companies, based on broad sub-sector trends and company specific issues •Analysing therapeutic areas, clinical trials designs and results as a base for investment decisions •Participated in initiations and reports on healthcare companies •Contributor on healthcare team publications, including monthly sketchbook, annual healthcare sector review, oncology market review.